DTN 051: First AI Discovered Drug Reaches Phase II Clinical Trials
The Big Picture
Insilico Medicine unveils first AI-generated and AI-discovered drug in new paper
“Insilico Medicine, the Hong Kong and New York-based biotech startup that has raised over $400 million to connect biology, chemistry, and clinical trial analysis using next-generation AI systems, announced a new paper today that highlights the journey of what it claims is the first AI-generated and AI-discovered drug — which has now reached Phase II clinical trials. The paper, in Nature Biotechnology, presents the entire journey of INS018_055, a drug candidate that was discovered using Insilico’s AI platform to treat idiopathic pulmonary fibrosis, a relatively rare but aggressive lung disease. The paper discloses the raw experimental data and the preclinical and clinical evaluation of the potentially first-in-class TNIK inhibitor discovered and designed through generative AI.” (VentureBeat)
Deep Tech News
- Colossal Biosciences creates induced pluripotent stem cells from elephant skin cells
- F-35A officially certified to carry nuclear bomb
- MIT Claims Superconducting Breakthrough Means Fusion Power Can Be Practical
- NASA satellite, Russian spacecraft crossed within 65 ft (20M) of each other
- Claude 3 Opus reinvented this quantum algorithm from scratch in just 2 prompts
JPEG of the Week
Peer Review
- Using light to precisely control single-molecule devices
- Scientists use a new type of nanoparticle that can both deliver vaccines and act as an adjuvant
- Scientists develop new machine learning method for modeling chemical reactions
- Scientists propose new scheme for the quantum battery using waveguides
- New tech to remanufacture recycled perovskite solar cells
- 3D printed titanium structure shows supernatural strength
Funding x M&A
- Multiverse raises $27M for quantum software targeting LLM leviathans
- Satellite servicing tech startup, led by former head of Ukraine’s space agency, lands $4M
- Artemis Fund has a fresh $36M to back diverse founders solving ‘big, hairy problems’
- Rakuten Medical, a biotech company developing cell-targeting therapies, raised a $119M Series E
- Zama, a startup building homomorphic encryption tech, raised a $73M Series A
- Quantum infrastructure company Maybell Quantum raised a $25M Series A
- Wobble Genomics, a startup providing a novel approach to RNA sequencing, raised an $11.8M round
- Vescent, a startup building quantum hardware, raised a $5M seed round
- Glacier, a startup building recycling robotics, raised a $7.7M round
- Kurs Orbital, a startup building satellite servicing tech, raised a $4M seed round
- Multiverse Computing, a startup building a quantum software platform, raised a $27M equity round
- AI-powered robotics startup Rios Intelligent Machines raised a $13M Series B
Miscellanea
How long will advanced civilizations try to communicate with us? / NASA unveils design for message heading to Jupiter's moon Europa / Claude 3 catches researchers testing it / Controversial new theory of gravity rules out need for dark matter / Engineer bought prison laptop and 1,200 incarcerated folks lost their devices / The Obscene Energy Demands of A.I / CSI in space: Analyzing bloodstain patterns in microgravity / Pentagon says no evidence of secret US work on alien tech / Tesla’s Berlin factory to shut down for days after suspected arson attack cuts power / Binance made crypto perfume in a baffling attempt to woo women / Thieves using cellular and Wi-Fi jammers to enter homes for robbery
a digital agency built for the future.
Haus Biographics is a digital agency in NYC that specializes in marketing and communications for deep tech organizations. Check out our website, follow us on Twitter, or say hello@hausb.io
